Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.

Saved in:
Bibliographic Details
Title: Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.
Authors: Siemens A; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; BC Children's Hospital Research Institute, Vancouver, Canada., Brooks B; Audiology and Speech Pathology Department, BC Children's Hospital, Vancouver, British Columbia, Canada., Rassekh SR; BC Children's Hospital Research Institute, Vancouver, Canada.; Division of Oncology, Hematology and Bone Marrow Transplant, British Columbia Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada., Meijer AJM; Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., van den Heuvel-Eibrink MM; Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Pediatric Oncology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, the Netherlands., Xu W; Department of Biostatistics, Dalla Lana School of Public Health, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada., Loucks CM; BC Children's Hospital Research Institute, Vancouver, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia.; Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, Canada., Ross CJD; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; BC Children's Hospital Research Institute, Vancouver, Canada.; Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada; and., Carleton BC; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; BC Children's Hospital Research Institute, Vancouver, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia.; Pharmaceutical Outcomes Programme, British Columbia Children's Hospital, Vancouver, Canada.
Corporate Authors: Canadian Pharmacogenomics Network for Drug Safety Consortium
Source: Therapeutic drug monitoring [Ther Drug Monit] 2023 Jun 01; Vol. 45 (3), pp. 345-353.
Publication Type: Journal Article
Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 7909660 Publication Model: Print Cited Medium: Internet ISSN: 1536-3694 (Electronic) Linking ISSN: 01634356 NLM ISO Abbreviation: Ther Drug Monit Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1536-3694
DOI:10.1097/FTD.0000000000001085